Theras in Vitadio's first Board of Advisors

When artificial intelligence talks to diabetes: agreement signed between two leading companies

The Italian Theras attends the first Board of Advisor of Vitadio, a company that offers one of the first certified digital therapies in the world.

Salsomaggiore Terme, 19 September 2023 - T-Investment, a Theras Group company, has recently acquired a stake in Vitadio, a company that boasts one of the world's first certified digital therapies for type 2 diabetes, with full coverage by a national reimbursement system, the German one, which today already sees over 8 thousand patients benefit from this therapy.

Theras, a leading company in the field of diabetes and chronic pain management, thus takes a further step forward thanks to its partnership with the Prague-based company.

"This partnership will contribute to strengthening Theras in the diabetes device sector, and it will do so by following the line we have been tracing for some years now, that of committing ourselves to sustainable solutions that can lead to a better quality of life for people," says Federico FERRARI, Managing Director of T-Investment, "and seize opportunities in the increasingly interconnected world of health and technology".

The table of the new Board of Advisors is thus populated, which on Monday 18 September, during the first meeting c/o the Theras Headquarters (see photo), saw the representatives of the companies come together for the first time.

 "We are thrilled to welcome on board - comments Jan Šomvársky, Co-Founder & CEO of Vitadio - "experienced partners who will help us take our company to the next level and thus fuel our mission of giving people control of their own health".

A partnership that was also born thanks to the important legal and fiscal advice of Studio Russo De Rosa Associati and the advisory services of Deloitte Officine Innovazione, which have supported Theras since the inception of this collaboration.

Vitadio's digital medical device Vitadio will be able to fit into disease management by making it easier for people with type 2 diabetes thanks to artificial intelligence and an innovative algorithm called Alfred, which offers personalised assistance to the patient directly on their smartphone, thus positively influencing their daily life. Vitadio supports its users holistically, helping them understand how diet, exercise, sleep, mental well-being and diabetes self-management affect their diabetes control and guides them to implement appropriate changes.

"This new generation of therapies, of which Vitadio is one of the forerunners worldwide, will mark an evolution in the approach to the management of type 2 diabetes, while also bringing with it a strong sustainable footprint, a crucial factor today, given the cost of public spending on this type of disease," says Matteo CENTOLA R&D Manager at Theras Lifetech.